

EXHIBIT 4



CONFIDENTIAL

24 June 2021

Scott Bizily
General Counsel
Synthego Corporation
3565 Haven Avenue, Suite #1
Menlo Park, California 94025 USA

SENT VIA EMAIL TO: Bizily, Scott <scott.bizily@synthego.com>

Re: Agilent Licensing Opportunities for Synthego re Modified CRISPR gRNAs

Dear Scott,

I hope that this finds you and your colleagues at Synthego doing well and staying healthy as the covid pandemic recedes, but am writing you today on behalf of Agilent to make you aware of certain licensing opportunities that Synthego may have with Agilent.

As you may know, Agilent is the owner of a significant portfolio of patents relating to modified CRISPR gRNAs (the "Patented Technology") which current list, so-labeled, is attached for your reference and review. Due to the broad adoption and use of this Patented Technology, Agilent, of course, has established a license program for those entities interested in using or continuing to use the Patented Technology.

It has come to our attention that Synthego may be interested in offering products or services for sale that benefit from or may benefit from this Patented Technology. In particular, your products, such as CRISPREVOLUTION Synthetic sgRNA which include modified gRNAs, and/or any of your services the performance of which use modified gRNAs or which result in the transfer of modified gRNAs to a customer, of course, would benefit from such a license.

Agilent would like to make Synthego more fully aware of the existence and extent of these patents and the technology they cover. Scientific reports have demonstrated the many benefits of the Patented Technology in various CRISPR-mediated genetic manipulations.

Thank you for your consideration of this opportunity and, in advance, for a reply to me and Dick Evans, our IP Counsel in this regard by 03 July 2021 as we look forward to having a very productive discussion regarding these licensing opportunities at that time or at another time arranged to occur shortly thereafter.

Meanwhile, of course, we wish you and your colleagues the best of health and safety in these trying times.

Sincerely,

Thomas Redder, Associate Vice President II
Global Strategic Business Development and Licensing Transactions
Agilent Technologies, Inc.
5301 Stevens Creek Boulevard
Santa Clara, California 95051 USA
telephone: +1.408.553.7090
email: thomas_redder@agilent.com

cc: Dick Evans

Attachment: Agilent Patented Technology Available for License re Modified CRISPR gRNA

**Agilent Patented Technology Available for License re Modified CRISPR gRNAs**

Title	Country	Status	Pat/App Number	Grant Date
Guide RNA with Chemical Modifications	US	Issued	10900034	Jan 26, 2021
Guide RNA with Chemical Modifications	AU	Pending	2015355546	
Guide RNA with Chemical Modifications	CA	Pending	2,969,619	
Guide RNA with Chemical Modifications	CN	Issued	ZL201580075275.4	Apr 16, 2021
Guide RNA with Chemical Modifications	EP	Pending	15866342.7	
Guide RNA with Chemical Modifications	JP	Pending	2017-529610	
Guide RNA with Chemical Modifications	KR	Pending	10-2017-7018311	
Guide RNA with Chemical Modifications	US	Issued	10337001	Jul 2, 2019
Guide RNA with Chemical Modifications	US	Pending	17/103,678	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	US	Issued	10767175	Sep 8, 2020
High Specificity Genome Editing Using Chemically Modified Guide RNAs	US	Pending	62/562,979	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	AU	Pending	2017277918	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	CA	Pending	3,026,372	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	CN	Pending	201780049055.3	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	EP	Pending	17811048.2	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	JP	Pending	2018-564259	



Title	Country	Status	Pat/App Number	Grant Date
High Specificity Genome Editing Using Chemically Modified Guide RNAs	KR	Pending	2019-7000571	
High Specificity Genome Editing Using Chemically Modified Guide RNAs	US	Pending	16/929,948	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	AU	Pending	2016246450	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	CA	Pending	2,981,715	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	CN	Pending	201680032647.X	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	EP	Pending	16720220.9	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	JP	Pending	2017-552447	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	KR	Pending	2017-7031965	
Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Regulation	US	Pending	15/724,073	